5 Key Takeaways

• 1

  YUVEZZI™ is the first FDA-approved dual-agent eye drop for treating presbyopia in adults.

• 2

  The formulation combines carbachol and brimonidine tartrate to improve near visual acuity while preserving distance vision.

• 3

  FDA approval was based on two Phase 3 trials, BRIO I and BRIO II, involving over 800 patients.

• 4

  YUVEZZI demonstrated significant improvements in near vision without serious adverse events during extensive safety studies.

• 5

  The product is expected to be commercially available in the US by the second quarter of 2026.